The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.
本发明涉及一种固体口服剂型的药物组合物,包括(R)-7-(2-(1-(4-
丁氧基苯基)-2-甲基丙基
氨基)-1-羟乙基)-5-羟基苯并[d]
噻唑-2(3H)-酮
醋酸盐。